Biocelect Pty News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Nuvaxovid is New Zealand's only protein-based COVID-19 vaccine GAITHERSBURG, Md., Aug. 18, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that New Zealand's Medsafe has granted expanded provisional approval for Nuvaxovid (NVX-CoV2373) COVID-19 vaccine for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in adolescents aged 12 through 17. "We are ...

Nuvaxovid is New Zealand's only protein-based COVID-19 vaccine GAITHERSBURG, Md., Aug. 18, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that New Zealand's Medsafe has granted expanded provisional approval for Nuvaxovid (NVX-CoV2373) COVID-19 vaccine for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in adolescents aged 12 through 17. "We are ...

Press release content from PR Newswire. The AP news staff was not involved in its creation.

(RTTNews) - Novavax Inc. (NVAX) said Wednesday that New Zealand's Medsafe has granted expanded provisional approval for Nuvaxovid (NVX-CoV2373) CO...

Nuvaxovid™ is the first protein-based COVID-19 vaccine available for use in adolescents aged 12 through 17 in Australia GAITHERSBURG, Md.,...